Under the deal, NorthStar's Ac-225, a radioactive alpha-particle emitter, will be used in Convergent's proprietary drug candidate, CONV 01-α. The drug is a monoclonal antibody conjugated with actinium-225.
The drug candidate is a major component of Convergent's peptide receptor radionuclide therapy (PRRT) technology. PRRT targets prostate-specific membrane antigen present in prostate cancer cells.
Copyright © 2022 AuntMinnie.com